News Releases

May 9, 2024
•  Q1 2024 revenue of $8.0 million , representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth •  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400 •  Management to hold conference call
May 1, 2024
DEER PARK, Ill. , May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen , Chief Executive Officer, and James Gruber , Chief